Leyden Labs gets $70M to test if nasal sprays can help protect against viruses

Kyle LaHucik

Senior Reporter

A Dutch biotech creating nasal sprays to protect against the flu and coronavirus has raised an additional $70 million and acquired a nimble Singapore startup …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Leyden Labs gets $70M to test if nasal sprays can help protect against viruses

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Versant unveils Light Horse with $62M and a partnership with Novartis

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear

IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Ley­den Labs gets $70M to test if nasal sprays can help pro­tect against virus­es

Senior Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Leyden Labs gets $70M to test if nasal sprays can help protect against viruses